Serina Therapeutics, Inc. 8-K

What Happened
Serina Therapeutics, Inc. (filed 8‑K on March 23, 2026) announced it entered a Securities Purchase Agreement on March 17, 2026 for a private placement led by Greg Bailey. Investors purchased common stock and pre‑funded warrants at $2.25 per share (or $2.2499 per pre‑funded warrant) and received redeemable warrants equal to 50% of the shares purchased. The initial closing was funded for $15.0 million as of March 20, 2026, with additional closings of at least $5.0M and up to $15.0M possible within specified 20‑day periods (the lead investor agreed to backstop the additional amount, subject to syndication).

Key Details

• Purchase Agreement dated March 17, 2026; initial closing funded $15.0 million on or before March 20, 2026.
• Price: $2.25 per common share (or $2.2499 per pre‑funded warrant). Redeemable warrants equal to 50% of shares purchased; exercise price $5.00; 4‑year term; not exercisable until six months after the Purchase Agreement date.
• Company may call (redeem) the redeemable warrants at $0.01 per underlying share upon the earlier of (i) 30 days after dosing first patient in Cohort 2 of SER‑252 Phase 1b SAD study or (ii) Sept 30, 2026, provided the stock trades at or above $10.00 (adjusted) on the business day before notice. Warrant holders get 30 days to exercise if called.
• Registration rights: company must file a resale registration statement no later than 45 days after at least $20M of securities sold; company bears fees and expenses.
• As condition to closing, the company amended its Senior Unsecured Convertible Promissory Note (dated Sept 9, 2025) to remove further obligations to borrow or loan under that note effective upon initial closing.
• Related‑party oversight: because Greg Bailey is a board designee of Juvenescence (a major shareholder), a special committee of independent directors approved the deal; shares to Dr. Bailey will not be issued unless and until stockholder approval required by NYSE American is obtained (company will seek approval at the next annual meeting and call additional meetings about every 90 days until approval).

Why It Matters
This filing documents a near‑term financing that provides Serina with at least $15.0M in cash now, plus the potential for additional funding. The deal adds common shares and multiple warrant instruments that can lead to further share issuance if exercised, and includes milestone‑linked warrant redemption tied to the company’s SER‑252 clinical progress and stock price. Investors should note the registration rights (which enable resale) and the related‑party safeguards (special committee approval and stockholder vote requirement for issuance to the lead investor). The SEC filing relied on exemptions for unregistered sales (Section 4(a)(2)/Rule 506(b)).